US FDA grants fast track designation to Radius Health's breast cancer drug
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
The U.S. Food and Drug Administration granted fast-track designation to Radius Health Inc.'s breast cancer drug estrogen.
The company said the drug is being evaluated in two ongoing phase 1 studies and will be evaluated in a phase 2 study in early 2018.
